<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542242</url>
  </required_header>
  <id_info>
    <org_study_id>PWS.VGH.UBC</org_study_id>
    <nct_id>NCT01542242</nct_id>
  </id_info>
  <brief_title>Liraglutide Use in Prader-Willi Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vancouver General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vancouver General Hospital</source>
  <brief_summary>
    <textblock>
      Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in
      patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive
      effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide
      use in the treatment of PWS is limited to one case report by Cyganek et el (See attached
      Citation). In this case report, the subject showed improvements in hemoglobin A1c and body
      weight over 14 weeks.

      The investigators plan to examine the use of liraglutide in a single subject with Prader
      Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical
      parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid
      control.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Subject withdrew
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Change from baseline in A1C at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose (mmol/L)</measure>
    <time_frame>Change from baseline in fasting blood glucose at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Insulin level</measure>
    <time_frame>Change from baseline in fasting blood insulin at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight (kg)</measure>
    <time_frame>Change from baseline in body weight at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile</measure>
    <time_frame>Change from baseline in fasting lipid profile at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Circumference (cm)</measure>
    <time_frame>Change from baseline in hip circumference at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Adipose Tissue Distribution (whole body Computed Tomography)</measure>
    <time_frame>Change from baseline in total body adipose tissue distribution at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Prader Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prader Willi Syndrome, Diabetes Type 2

        Exclusion Criteria:

          -  Previous or family history of Medullary Carcinoma of the Thyroid or multiple endocrine
             neoplasia syndrome.

          -  Subjects with acute or chronic Pancreatitis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Kong, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver General Hospital, University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vancouver General Hospital - Diamond Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 2011 Jun;28(6):755-6. doi: 10.1111/j.1464-5491.2011.03280.x.</citation>
    <PMID>21388446</PMID>
  </reference>
  <reference>
    <citation>Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, Sainsbury A, Steinbeck K, Campbell LV, Viardot A. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011 Aug;96(8):E1314-9. doi: 10.1210/jc.2011-0038. Epub 2011 Jun 1.</citation>
    <PMID>21632815</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vancouver General Hospital</investigator_affiliation>
    <investigator_full_name>David E. Harris, MD</investigator_full_name>
    <investigator_title>MD, Clinical Endocrinology Fellow, University of British Columbia</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Prader Willi Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

